Paul Kelly Marcom | Scholars@Duke

Paul Kelly Marcom
Associate Professor of Medicine

Basic Science:
-Germline and somatic genetic changes in cancer, particularly breast cancer. Ongoing efforts with Dr. Joseph R. Nevins in Department of Genetics.

Translational:
-Identification and management of individuals and families with hereditary cancer risk.
-Communication of cancer risk information to individuals and families.
-Breast cancer prevention.
-Optimizing management of early breast cancer.
-Treatment of metastatic breast cancer

Dr. Marcom's research has focused on two main areas. First, in the laboratory of Dr. Joseph Nevins in the Department of Genetics, he has been investigating alterations in cell cycle control in cancer. Primarily, these experiments have looked for primary alterations in the E2F family of genes, and their possible contribution to developing cancer. More recently, he has been involved with issues regarding genetic predisposition to developing cancer.

Investigations of cell cycle alterations have employed standard molecular biology techniques to analyze both cell lines and primary tumors for alterations in control of the retinoblastoma pathway, and consequent effects on E2F control.

Clinically, Dr. Marcom works as a medical oncologist in the multidisciplinary breast cancer clinic. He participates in clinical trials investigating new chemotherapeutic and biologic treatments. In addition, he is developing a new high risk, familial cancer clinic. This clinic will see patients and families thought to be at high risk of developing malignancies, and will interface with the forming Cancer Genetics Network. Patients and families will be counseled about their cancer risk, and identified for studying issues related to cancer genetics: determining penetrance of identified gene mutations, determining factors modifying genetic risk, prevention studies, etc. Finally, he also plans to be involved in clinical evaluation of drugs inhibiting tumor angiogenesis.

Areas of developing expertise include cell cycle alterations in malignancy, breast cancer, and hereditary cancer genetics.

Breast cancer, cell cycle, genetics, familial cancer, prognostic factors, angiogenesis

Current Appointments & Affiliations

Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2013
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1989

Contact Information

10 Bryan Searle Drive, Room 461 Seeley G. Mudd Building, Durham, NC 27710
Duke Box 3147, Durham, NC 27710
marco001@mc.duke.edu (919) 684-3877

Background
Education, Training, & Certifications
- Fellow In Hematology Oncology, Medicine, Duke University 1992 - 1995
- Medical Resident, Medicine, Duke University 1989 - 1992
- M.D., Baylor University 1989
Duke Appointment History
- Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2010 - 2013
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2004 - 2010
- Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1997 - 2004
- Instructor, Temporary in the Medicine, Medicine, Medical Oncology, Medicine 1997
Research
Selected Grants
- Merck KEYNOTE 522 (MK-3475) awarded by Merck Sharp & Dohme 2017 - 2022
- Postdoctoral training in genomic medicine research awarded by National Institutes of Health 2017 - 2022
- Targeting precursor neural (N)-cadherin to eliminate chemotherapy-resistant triple-negative breast tumor cells awarded by Department of Defense 2017 - 2020
- TBCRC 031 INFORM awarded by Johns Hopkins University 2015 - 2019
- TBCRC 031 INFORM (Beth Israel) awarded by Beth Israel Deaconess Medical Center 2015 - 2019
- Can contrast dynamics in breast MRI predict genomic intra-tumor heterogeneity awarded by Bracco Diagnostics, Inc. 2016 - 2018
- A randomized phase II study of adjuvant Trastuzumab emtansine (T-DM1) vs Paclitaxel awarded by Dana Farber Cancer Institute 2014 - 2018
- A RANDOMIZED PHASE II STUDY OF PREOPERATIVE CISPLATIN VS PACLITAXEL IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER awarded by Dana Farber Cancer Institute 2014 - 2018
- Novartis BYL719A2201 awarded by Novartis Pharmaceuticals Corporation 2013 - 2017
- Commericialization of a computational imaging-based biomarker for prognostication in breast cancer awarded by North Carolina Biotechnology Center 2016 - 2017
- Targeting nuclear FGF receptor to improve chemotherapy response in triple-negative breast cancer awarded by Department of Defense 2013 - 2016
- Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
- Randomized Trial of Optimal Type of Aerobic Training in Breast Cancer awarded by National Institutes of Health 2010 - 2014
- Programs in Clinical Effectiveness of Cancer Pharmacogenomics awarded by National Institutes of Health 2009 - 2012
- Markers of short term breast cancer risk in FNA awarded by National Institutes of Health 1995 - 2008
- Phase II trial of Cetuximab & Carboplatin in Basal-like Breast Cancer awarded by National Institutes of Health 1995 - 2008
- Carolina and Georgia Genetics Network Center awarded by National Institutes of Health 1998 - 2008
- Phase II Trial of Estradiol Therapy for Advanced Breast Cancer awarded by National Institutes of Health 2003 - 2005
- Carolina and Georgia Genetics Network Center awarded by National Institutes of Health 1998 - 2004
Publications & Artistic Works
Selected Publications
- Conference Papers
  - Irwin, B, Kimmick, G, Altomare, I, Marcom, PK, Houck, K, Zafar, SY, and Peppercorn, J. "Patient experience and attitudes toward addressing the cost of breast cancer care." November 2014. Full Text
  - Madhav, P, Cutler, S, Crotty, D, Perez, K, McKinley, R, Marcom, P, Wong, T, and Tornai, M. "TU-C-332-04: Pilot Patient Studies Using a Dedicated Dual-Modality SPECT-CT System for Breast Imaging." June 2008. Full Text
- Journal Articles
  - Harowicz, MR, Saha, A, Grimm, LJ, Marcom, PK, Marks, JR, Hwang, ES, and Mazurowski, MA. "Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?." Journal of magnetic resonance imaging : JMRI (February 9, 2017). Full Text
  - Buchanan, AH, Voils, CI, Schildkraut, JM, Fine, C, Horick, NK, Marcom, PK, Wiggins, K, and Skinner, CS. "Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation." Journal of genetic counseling 26, no. 1 (February 2017): 79-92. Full Text
  - Harowicz, MR, Robinson, TJ, Dinan, MA, Saha, A, Marks, JR, Marcom, PK, and Mazurowski, MA. "Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset." Breast cancer research and treatment 162, no. 1 (February 2017): 1-10. (Review) Full Text
  - Nelson, ER, Li, S, Kennedy, M, Payne, S, Kilibarda, K, Groth, J, Bowie, M, Parilla-Castellar, E, de Ridder, G, Marcom, PK, Lyes, M, Peterson, BL, Cook, M, Pizzo, SV, McDonnell, DP, and Bachelder, RE. "Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface." Oncotarget 7, no. 51 (December 2016): 84030-84042. Full Text
  - Kamal, A, Zhang, T, Power, S, and Marcom, PK. "Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures." Journal of the National Comprehensive Cancer Network : JNCCN 14, no. 8 (August 2016): 993-998. Full Text
  - Kamal, A, Zhang, T, Power, S, and Marcom, PK. "Is advanced imaging in early-stage breast cancer ever warranted? Reconciling clinical judgment with common quality measures." JNCCN Journal of the National Comprehensive Cancer Network 14, no. 8 (August 1, 2016): 993-998.
  - Daly, MB, Pilarski, R, Axilbund, JE, Berry, M, Buys, SS, Crawford, B, Farmer, M, Friedman, S, Garber, JE, Khan, S, Klein, C, Kohlmann, W, Kurian, A, Litton, JK, Madlensky, L, Marcom, PK, Merajver, SD, Offit, K, Pal, T, Rana, H, Reiser, G, Robson, ME, Shannon, KM, Swisher, E, Voian, NC, Weitzel, JN, Whelan, A, Wick, MJ, Wiesner, GL, Dwyer, M, Kumar, R, and Darlow, S. "Genetic/familial high-risk assessment: Breast and ovarian, version 2.2015 Featured updates to the NCCN guidelines." JNCCN Journal of the National Comprehensive Cancer Network 14, no. 2 (February 1, 2016): 153-162. (Review)
  - Buchanan, AH, Datta, SK, Skinner, CS, Hollowell, GP, Beresford, HF, Freeland, T, Rogers, B, Boling, J, Marcom, PK, and Adams, MB. "Randomized Trial of Telegenetics vs. In-Person Cancer Genetic Counseling: Cost, Patient Satisfaction and Attendance." Journal of genetic counseling 24, no. 6 (December 2015): 961-970. Full Text
  - Gradishar, WJ, Anderson, BO, Balassanian, R, Blair, SL, Burstein, HJ, Cyr, A, Elias, AD, Farrar, WB, Forero, A, Giordano, SH, Goetz, M, Goldstein, LJ, Hudis, CA, Isakoff, SJ, Marcom, PK, Mayer, IA, McCormick, B, Moran, M, Patel, SA, Pierce, LJ, Reed, EC, Salerno, KE, Schwartzberg, LS, Smith, KL, Smith, ML, Soliman, H, Somlo, G, Telli, M, Ward, JH, Shead, DA, and Kumar, R. "Breast cancer, version 1.2016 featured updates to the NCCN guidelines." JNCCN Journal of the National Comprehensive Cancer Network 13, no. 12 (December 1, 2015): 1475-1485.
  - Mazurowski, MA, Grimm, LJ, Zhang, J, Marcom, PK, Yoon, SC, Kim, C, Ghate, SV, and Johnson, KS. "Recurrence-free survival in breast cancer is associated with MRI tumor enhancement dynamics quantified using computer algorithms." European journal of radiology 84, no. 11 (November 2015): 2117-2122. Full Text
  - Kimmick, G, Edmond, SN, Bosworth, HB, Peppercorn, J, Marcom, PK, Blackwell, K, Keefe, FJ, and Shelby, RA. "Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy." Breast (Edinburgh, Scotland) 24, no. 5 (October 2015): 630-636. Full Text
  - Sutton, LM, Geradts, J, Hamilton, EP, Havlin, KA, Kimmick, GG, Marcom, PK, Spector, NL, Watson, M, Rabin, DU, Bruno, TO, Noe, A, Miller, S, Subramaniam, C, Layton, S, and Grichnik, K. "CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers." Journal of the National Comprehensive Cancer Network : JNCCN 13, no. 8 (August 2015): 1005-1011. Full Text
  - Li, S, Payne, S, Wang, F, Claus, P, Su, Z, Groth, J, Geradts, J, de Ridder, G, Alvarez, R, Marcom, PK, Pizzo, SV, and Bachelder, RE. "Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance." Breast cancer research : BCR 17 (July 4, 2015): 91-. Full Text
  - Silva, GO, He, X, Parker, JS, Gatza, ML, Carey, LA, Hou, JP, Moulder, SL, Marcom, PK, Ma, J, Rosen, JM, and Perou, CM. "Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer." Breast cancer research and treatment 152, no. 2 (July 2015): 347-356. Full Text
  - Ruddy, KJ, Guo, H, Barry, W, Dang, CT, Yardley, DA, Moy, B, Marcom, PK, Albain, KS, Rugo, HS, Ellis, MJ, Shapira, I, Wolff, AC, Carey, LA, Overmoyer, BA, Hudis, C, Krop, IE, Burstein, HJ, Winer, EP, Partridge, AH, and Tolaney, SM. "Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial)." Breast cancer research and treatment 151, no. 3 (June 2015): 589-596. Full Text
  - Yadav, BS, Sharma, SC, Robin, TP, Sams, S, Elias, AD, Kaklamani, V, Kelly Marcom, P, Schaefer, S, and Morris, GJ. "Synchronous primary carcinoma of breast and ovary versus ovarian metastases." Seminars in oncology 42, no. 2 (April 2015): e13-e24. (Review) Full Text
  - Magbanua, MJM, Carey, LA, DeLuca, A, Hwang, J, Scott, JH, Rimawi, MF, Mayer, EL, Marcom, PK, Liu, MC, Esteva, FJ, Park, JW, Rugo, HS, and Translational Breast Cancer Research Consortium, . "Circulating tumor cell analysis in metastatic triple-negative breast cancers." Clinical cancer research : an official journal of the American Association for Cancer Research 21, no. 5 (March 2015): 1098-1105. Full Text
  - Grimm, LJ, Johnson, KS, Marcom, PK, Baker, JA, and Soo, MS. "Can breast cancer molecular subtype help to select patients for preoperative MR imaging?." Radiology 274, no. 2 (February 2015): 352-358. Full Text
  - Barry, WT, Perou, CM, Marcom, PK, Carey, LA, and Ibrahim, JG. "The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies." Journal of biopharmaceutical statistics 25, no. 1 (January 2015): 66-88. Full Text
  - Gradishar, WJ, Anderson, BO, Balassanian, R, Blair, SL, Burstein, HJ, Cyr, A, Elias, AD, Farrar, WB, Forero, A, Giordano, SH, Goetz, M, Goldstein, LJ, Hudis, CA, Isakoff, SJ, Marcom, PK, Mayer, IA, McCormick, B, Moran, M, Patel, SA, Pierce, LJ, Reed, EC, Salerno, KE, Schwartzberg, LS, Smith, KL, Smith, ML, Soliman, H, Somlo, G, Telli, M, Ward, JH, Shead, DA, and Kumar, R. "Breast cancer version 2.2015: Clinical practice guidelines in oncology." JNCCN Journal of the National Comprehensive Cancer Network 13, no. 4 (January 1, 2015): 448-475. (Review)
  - Gwin, WR, and Marcom, PK. "Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: A prospective study." Breast Diseases 25, no. 4 (January 1, 2015): 326-327.
  - Li, S, Payne, S, Wang, F, Claus, P, Su, Z, Groth, J, Geradts, J, Ridder, GD, Alvarez, R, Marcom, PK, Pizzo, SV, and Bachelder, RE. "Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance." Breast Cancer Research (2015). Full Text
  - Mazurowski, MA, Grimm, LJ, Zhang, J, Marcom, PK, Yoon, SC, Kim, C, Ghate, SV, and Johnson, KS. "Recurrence-free survival in breast cancer is associated with MRI tumor enhancement dynamics quantified using computer algorithms." European Journal of Radiology 84, no. 11 (2015): 2117-2122. Full Text
  - Tolaney, SM, Barry, WT, Dang, CT, Yardley, DA, Moy, B, Marcom, PK, Albain, KS, Rugo, HS, Ellis, M, Shapira, I, Wolff, AC, Carey, LA, Overmoyer, BA, Partridge, AH, Guo, H, Hudis, CA, Krop, IE, Burstein, HJ, and Winer, EP. "Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer." The New England journal of medicine 372, no. 2 (January 2015): 134-141. Full Text
  - Irwin, B, Kimmick, G, Altomare, I, Marcom, PK, Houck, K, Zafar, SY, and Peppercorn, J. "Patient Experience and Attitudes Toward Addressing the Cost of Breast Cancer Care." ONCOLOGIST 19, no. 11 (November 2014): 1135-1140. Full Text Link to Item
  - Shelby, RA, Edmond, SN, Wren, AA, Keefe, FJ, Peppercorn, JM, Marcom, PK, Blackwell, KL, and Kimmick, GG. "Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 22, no. 10 (October 2014): 2851-2859. Full Text
  - Daly, MB, Pilarski, R, Axilbund, JE, Buys, SS, Crawford, B, Friedman, S, Garber, JE, Horton, C, Kaklamani, V, Klein, C, Kohlmann, W, Kurian, A, Litton, J, Madlensky, L, Marcom, PK, Merajver, SD, Offit, K, Pal, T, Pasche, B, Reiser, G, Shannon, KM, Swisher, E, Voian, NC, Weitzel, JN, Whelan, A, Wiesner, GL, Dwyer, MA, Kumar, R, and National comprehensive cancer network, . "Genetic/familial high-risk assessment: breast and ovarian, version 1.2014." Journal of the National Comprehensive Cancer Network : JNCCN 12, no. 9 (September 2014): 1326-1338. Full Text
  - Anders, C, Deal, AM, Abramson, V, Liu, MC, Storniolo, AM, Carpenter, JT, Puhalla, S, Nanda, R, Melhem-Bertrandt, A, Lin, NU, Kelly Marcom, P, Van Poznak, C, Stearns, V, Melisko, M, Smith, JK, Karginova, O, Parker, J, Berg, J, Winer, EP, Peterman, A, Prat, A, Perou, CM, Wolff, AC, and Carey, LA. "TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases." Breast cancer research and treatment 146, no. 3 (August 2014): 557-566. Full Text
  - Gradishar, WJ, Anderson, BO, Blair, SL, Burstein, HJ, Cyr, A, Elias, AD, Farrar, WB, Forero, A, Giordano, SH, Goldstein, LJ, Hayes, DF, Hudis, CA, Isakoff, SJ, Ljung, B-ME, Marcom, PK, Mayer, IA, McCormick, B, Miller, RS, Pegram, M, Pierce, LJ, Reed, EC, Salerno, KE, Schwartzberg, LS, Smith, ML, Soliman, H, Somlo, G, Ward, JH, Wolff, AC, Zellars, R, Shead, DA, Kumar, R, and NCCN, . "Breast Cancer Version 3.2014 Clinical Practice Guidelines in Oncology." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK 12, no. 4 (April 2014): 542-590. Link to Item
  - Gradishar, WJ, Anderson, BO, Blair, SL, Burstein, HJ, Cyr, A, Elias, AD, Farrar, WB, Forero, A, Giordano, SH, Goldstein, LJ, Hayes, DF, Hudis, CA, Isakoff, SJ, Ljung, B-ME, Marcom, PK, Mayer, IA, McCormick, B, Miller, RS, Pegram, M, Pierce, LJ, Reed, EC, Salerno, KE, Schwartzberg, LS, Smith, ML, Soliman, H, Somlo, G, Ward, JH, Wolff, AC, Zellars, R, Shead, DA, Kumar, R, and National Comprehensive Cancer Network Breast Cancer Panel, . "Breast cancer version 3.2014." Journal of the National Comprehensive Cancer Network : JNCCN 12, no. 4 (April 2014): 542-590. Full Text
  - Kamal, AH, Power, S, Broadwater, G, Holland, AR, and Marcom, PK. "Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute." Journal of the National Comprehensive Cancer Network : JNCCN 12 Suppl 1 (February 2014): S21-S24. Full Text
  - Anders, C, Deal, AM, Abramson, V, Liu, MC, Storniolo, AM, Carpenter, JT, Puhalla, S, Nanda, R, Melhem-Bertrandt, A, Lin, NU, Kelly Marcom, P, Van Poznak, C, Stearns, V, Melisko, M, Smith, JK, Karginova, O, Parker, J, Berg, J, Winer, EP, Peterman, A, Prat, A, Perou, CM, Wolff, AC, and Carey, LA. "TBCRC 018: Phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases." Breast Cancer Research and Treatment 146, no. 3 (January 1, 2014): 557-566. Full Text
  - Shelby, RA, Edmond, SN, Wren, AA, Keefe, FJ, Peppercorn, JM, Marcom, PK, Blackwell, KL, and Kimmick, GG. "Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy." Supportive Care in Cancer 22, no. 10 (2014): 2851-2859. Full Text
  - Hamilton, E, Kimmick, G, Hopkins, J, Marcom, PK, Rocha, G, Welch, R, Broadwater, G, and Blackwell, K. "Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer." Clinical Breast Cancer 13, no. 6 (December 1, 2013): 416-420. Full Text
  - Hamilton, E, Kimmick, G, Hopkins, J, Marcom, PK, Rocha, G, Welch, R, Broadwater, G, and Blackwell, K. "Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer." Clin Breast Cancer 13, no. 6 (December 2013): 416-420. Full Text Link to Item
  - Peppercorn, J, Hamilton, E, Marcom, PK, Beskow, L, and Lyman, GH. "Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen." Cancer 119, no. 20 (October 15, 2013): 3703-3709. Full Text Link to Item
  - Jones, LW, Fels, DR, West, M, Allen, JD, Broadwater, G, Barry, WT, Wilke, LG, Masko, E, Douglas, PS, Dash, RC, Povsic, TJ, Peppercorn, J, Marcom, PK, Blackwell, KL, Kimmick, G, Turkington, TG, and Dewhirst, MW. "Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy." Cancer Prev Res (Phila) 6, no. 9 (September 2013): 925-937. Full Text Link to Item
  - Theriault, RL, Carlson, RW, Allred, C, Anderson, BO, Burstein, HJ, Edge, SB, Farrar, WB, Forero, A, Giordano, SH, Goldstein, LJ, Gradishar, WJ, Hayes, DF, Hudis, CA, Isakoff, SJ, Ljung, B-ME, Mankoff, DA, Marcom, PK, Mayer, IA, McCormick, B, Pierce, LJ, Reed, EC, Schwartzberg, LS, Smith, ML, Soliman, H, Somlo, G, Ward, JH, Wolff, AC, Zellars, R, Shead, DA, Kumar, R, and National Comprehensive Cancer Network, . "Breast cancer, version 3.2013: featured updates to the NCCN guidelines." J Natl Compr Canc Netw 11, no. 7 (July 2013): 753-760. Link to Item
  - Edmond, SN, Shelby, RA, Kimmick, GG, Marcom, PK, Peppercorn, JM, and Keefe, FJ. "Symptom communication in breast cancer: relationships of holding back and self-efficacy for communication to symptoms and adjustment." J Psychosoc Oncol 31, no. 6 (2013): 698-711. Full Text Link to Item
  - Greenup, R, Buchanan, A, Lorizio, W, Rhoads, K, Chan, S, Leedom, T, King, R, McLennan, J, Crawford, B, Marcom, PK, and al, E. "Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort." Annals of Surgical Oncology 20, no. 10 (2013): 3254-3258. Full Text
  - Greenup, R, Buchanan, A, Lorizio, W, Rhoads, K, Chan, S, Leedom, T, King, R, McLennan, J, Crawford, B, Marcom, PK, and al, E. "Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort." Annals of Surgical Oncology (2013): 1-5. Full Text
  - Peppercorn, J, Hamilton, E, Marcom, PK, Beskow, L, and Lyman, GH. "Pharmacogenetic testing in the face of unclear clinical efficacy: Lessons from cytochrome P450 2D6 for tamoxifen." Cancer 119, no. 20 (2013): 3703-3709. Full Text
  - Johnson, KS, Bentley, RC, Kelly Marcom, P, and Baker, JA. "Pseudoangiomatous stromal hyperplasia (PASH) causing massive breast enlargement: MRI findings." Breast J 18, no. 6 (November 2012): 600-601. Full Text Link to Item
  - Vaz-Luis, I, Ottesen, RA, Hughes, ME, Marcom, PK, Moy, B, Rugo, HS, Theriault, RL, Wilson, J, Niland, JC, Weeks, JC, and Lin, NU. "Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. (Published online)" Breast Cancer Res 14, no. 5 (October 1, 2012): R129-. Full Text Link to Item
  - Strickler, JH, Starodub, AN, Jia, J, Meadows, KL, Nixon, AB, Dellinger, A, Morse, MA, Uronis, HE, Marcom, PK, Zafar, SY, Haley, ST, and Hurwitz, HI. "Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors." Cancer Chemother Pharmacol 70, no. 2 (August 2012): 251-258. Full Text Link to Item
  - Carey, LA, Rugo, HS, Marcom, PK, Mayer, EL, Esteva, FJ, Ma, CX, Liu, MC, Storniolo, AM, Rimawi, MF, Forero-Torres, A, Wolff, AC, Hobday, TJ, Ivanova, A, Chiu, W-K, Ferraro, M, Burrows, E, Bernard, PS, Hoadley, KA, Perou, CM, and Winer, EP. "TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer." J Clin Oncol 30, no. 21 (July 20, 2012): 2615-2623. Full Text Link to Item
  - Carlson, RW, Allred, DC, Anderson, BO, Burstein, HJ, Edge, SB, Farrar, WB, Forero, A, Giordano, SH, Goldstein, LJ, Gradishar, WJ, Hayes, DF, Hudis, CA, Isakoff, SJ, Ljung, B-ME, Mankoff, DA, Marcom, PK, Mayer, IA, McCormick, B, Pierce, LJ, Reed, EC, Smith, ML, Soliman, H, Somlo, G, Theriault, RL, Ward, JH, Wolff, AC, Zellars, R, Kumar, R, Shead, DA, and National Comprehensive Cancer Network, . "Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines." J Natl Compr Canc Netw 10, no. 7 (July 1, 2012): 821-829. Link to Item
  - Hassett, MJ, Silver, SM, Hughes, ME, Blayney, DW, Edge, SB, Herman, JG, Hudis, CA, Marcom, PK, Pettinga, JE, Share, D, Theriault, R, Wong, Y-N, Vandergrift, JL, Niland, JC, and Weeks, JC. "Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer." J Clin Oncol 30, no. 18 (June 20, 2012): 2218-2226. Full Text Link to Item
  - Ellis, MJ, Ding, L, Shen, D, Luo, J, Suman, VJ, Wallis, JW, Van Tine, BA, Hoog, J, Goiffon, RJ, Goldstein, TC, Ng, S, Lin, L, Crowder, R, Snider, J, Ballman, K, Weber, J, Chen, K, Koboldt, DC, Kandoth, C, Schierding, WS, McMichael, JF, Miller, CA, Lu, C, Harris, CC, McLellan, MD, Wendl, MC, DeSchryver, K, Allred, DC, Esserman, L, Unzeitig, G, Margenthaler, J, Babiera, GV, Marcom, PK, Guenther, JM, Leitch, M, Hunt, K, Olson, J, Tao, Y, Maher, CA, Fulton, LL, Fulton, RS, Harrison, M, and Oberkfell, B et al. "Whole-genome analysis informs breast cancer response to aromatase inhibition. (Published online)" Nature 486, no. 7403 (June 10, 2012): 353-360. Full Text Link to Item
  - Acharya, CR, Hsu, DS, Anders, CK, Anguiano, A, Salter, KH, Walters, KS, Redman, RC, Tuchman, SA, Moylan, CA, Mukherjee, S, Barry, WT, Dressman, HK, Ginsburg, GS, Marcom, KP, Garman, KS, Lyman, GH, Nevins, JR, and Potti, A. "Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587." JAMA 307, no. 5 (February 1, 2012): 453-. Full Text Link to Item
  - Herold, CI, Chadaram, V, Peterson, BL, Marcom, PK, Hopkins, J, Kimmick, GG, Favaro, J, Hamilton, E, Welch, RA, Bacus, S, and Blackwell, KL. "Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing." Clin Cancer Res 17, no. 18 (September 15, 2011): 6061-6070. Full Text Link to Item
  - Armstrong, AJ, Marengo, MS, Oltean, S, Kemeny, G, Bitting, RL, Turnbull, JD, Herold, CI, Marcom, PK, George, DJ, and Garcia-Blanco, MA. "Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers." Mol Cancer Res 9, no. 8 (August 2011): 997-1007. Full Text Link to Item
  - Ellis, MJ, Suman, VJ, Hoog, J, Lin, L, Snider, J, Prat, A, Parker, JS, Luo, J, DeSchryver, K, Allred, DC, Esserman, LJ, Unzeitig, GW, Margenthaler, J, Babiera, GV, Marcom, PK, Guenther, JM, Watson, MA, Leitch, M, Hunt, K, and Olson, JA. "Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031." J Clin Oncol 29, no. 17 (June 10, 2011): 2342-2349. Full Text Link to Item
  - Bild, AH, Parker, JS, Gustafson, AM, Acharya, CR, Hoadley, KA, Anders, C, Marcom, PK, Carey, LA, Potti, A, Nevins, JR, and Perou, CM. "Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer." Breast Cancer Research 13, no. 4 (2011). Full Text
  - Carlson, RW, Allred, DC, Anderson, BO, Burstein, HJ, Carter, WB, Edge, SB, Erban, JK, Farrar, WB, Forero, A, Giordano, SH, Goldstein, LJ, Gradishar, WJ, Hayes, DF, Hudis, CA, Ljung, B-M, Mankoff, DA, Marcom, PK, Mayer, IA, McCormick, B, Pierce, LJ, Reed, EC, Sachdev, J, Smith, ML, Somlo, G, Ward, JH, Wolff, AC, and Zellars, R. "Invasive breast cancer: Clinical practice guidelines in oncology." JNCCN Journal of the National Comprehensive Cancer Network 9, no. 2 (2011): 136-222.
  - Dominici, L, Najita, J, Hughes, M, Niland, J, Marcom, P, Wong, Y-N, Carter, B, Javid, S, Edge, S, Burstein, H, and Golshan, M. "Surgery of the primary tumor does not improve survival in stage IV breast cancer." Breast Cancer Research and Treatment 129, no. 2 (2011): 459-465. Full Text
  - Il'yasova, D, Kennedy, K, Spasojevic, I, Wang, F, Tolun, AA, Base, K, Young, SP, Kelly Marcom, P, Marks, J, Millington, DS, and Dewhirst, MW. "Individual responses to chemotherapy-induced oxidative stress." Breast Cancer Res Treat 125, no. 2 (January 2011): 583-589. Full Text Link to Item
  - Salter, KH, Acharya, CR, Walters, KS, Redman, R, Anguiano, A, Garman, KS, Anders, CK, Mukherjee, S, Dressman, HK, Barry, WT, Marcom, KP, Olson, J, Nevins, JR, and Potti, A. "An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer." PLoS ONE 6, no. 9 (2011). Full Text
  - Moorman, PG, Iversen, ES, Marcom, PK, Marks, JR, Wang, F, Kathleen Cuningham Consortium for Research into Familial Breast Cancer, , Lee, E, Ursin, G, Rebbeck, TR, Domchek, SM, Arun, B, Susswein, L, Isaacs, C, Garber, JE, Visvanathan, K, Griffin, CA, Sutphen, R, Brzosowicz, J, Gruber, S, Finkelstein, DM, and Schildkraut, JM. "Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis." Breast Cancer Res Treat 124, no. 2 (November 2010): 441-451. Full Text Link to Item
  - Rumble, ME, Keefe, FJ, Edinger, JD, Affleck, G, Marcom, PK, and Shaw, HS. "Contribution of cancer symptoms, dysfunctional sleep related thoughts, and sleep inhibitory behaviors to the insomnia process in breast cancer survivors: a daily process analysis." Sleep 33, no. 11 (November 2010): 1501-1509. Link to Item
  - Jones, LW, Douglas, PS, Eves, ND, Marcom, PK, Kraus, WE, Herndon, JE, Inman, BA, Allen, JD, and Peppercorn, J. "Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer. (Published online)" BMC Cancer 10 (October 6, 2010): 531-. Full Text Open Access Copy Link to Item
  - Carlson, RW, Allred, DC, Anderson, BO, Burstein, HJ, Carter, WB, Edge, SB, Erban, JK, Farrar, WB, Forero, A, Giordano, SH, Goldstein, LJ, Gradishar, WJ, Hayes, DF, Hudis, CA, Ljung, B-M, Marcom, PK, Mayer, IA, McCormick, B, Pierce, LJ, Reed, EC, Smith, ML, Somlo, G, Topham, NS, Ward, JH, Winer, EP, and Wolff, AC. "Breast cancer: noninvasive and special situations." J Natl Compr Canc Netw 8, no. 10 (October 2010): 1182-1207. Link to Item
  - Lipkus, IM, Peters, E, Kimmick, G, Liotcheva, V, and Marcom, P. "Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy." Med Decis Making 30, no. 4 (July 2010): 464-473. Full Text Link to Item
  - Il'yasova, D, Spasojevic, I, Wang, F, Tolun, AA, Base, K, Young, SP, Marcom, PK, Marks, J, Mixon, G, DiGiulio, R, and Millington, DS. "Urinary biomarkers of oxidative status in a clinical model of oxidative assault." Cancer Epidemiol Biomarkers Prev 19, no. 6 (June 2010): 1506-1510. Full Text Link to Item
  - Barry, WT, Kernagis, DN, Dressman, HK, Griffis, RJ, Hunter, JD, Olson, JA, Marks, JR, Ginsburg, GS, Marcom, PK, Nevins, JR, Geradts, J, and Datto, MB. "Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome." J Clin Oncol 28, no. 13 (May 1, 2010): 2198-2206. Full Text Link to Item
  - Daly, MB, Axilbund, JE, Buys, S, Crawford, B, Farrell, CD, Friedman, S, Garber, JE, Goorha, S, Gruber, SB, Hampel, H, Kaklamani, V, Kohlmann, W, Kurian, A, Litton, J, Marcom, PK, Nussbaum, R, Offit, K, Pal, T, Pasche, B, Pilarski, R, Reiser, G, Shannon, KM, Smith, JR, Swisher, E, and Weitzel, JN. "Genetic/familial high-risk assessment: Breast and ovarian - Clinical practice guidelines in oncology™." JNCCN Journal of the National Comprehensive Cancer Network 8, no. 5 (2010): 562-594.
  - Tebbit, CL, Zhai, J, Untch, BR, Ellis, MJ, Dressman, HK, Bentley, RC, Baker, JA, Marcom, PK, Nevins, JR, Marks, JR, and Olson, JA. "Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care." Breast Cancer Res Treat 118, no. 3 (December 2009): 635-643. Full Text Link to Item
  - Ellis, MJ, Gao, F, Dehdashti, F, Jeffe, DB, Marcom, PK, Carey, LA, Dickler, MN, Silverman, P, Fleming, GF, Kommareddy, A, Jamalabadi-Majidi, S, Crowder, R, and Siegel, BA. "Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study." JAMA 302, no. 7 (August 19, 2009): 774-780. Full Text Link to Item
  - Il'yasova, D, Mixon, G, Wang, F, Marcom, PK, Marks, J, Spasojevich, I, Craft, N, Arredondo, F, and DiGiulio, R. "Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administration." Biomarkers 14, no. 5 (August 2009): 321-325. Full Text Link to Item
  - Olson, JA, Budd, GT, Carey, LA, Harris, LA, Esserman, LJ, Fleming, GF, Marcom, PK, Leight, GS, Giuntoli, T, Commean, P, Bae, K, Luo, J, and Ellis, MJ. "Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial." J Am Coll Surg 208, no. 5 (May 2009): 906-914. Full Text Link to Item
  - Partridge, AH, Wolff, AC, Marcom, PK, Kaufman, PA, Zhang, L, Gelman, R, Moore, C, Lake, D, Fleming, GF, Rugo, HS, Atkins, J, Sampson, E, Collyar, D, and Winer, EP. "The impact of sharing results of a randomized breast cancer clinical trial with study participants." Breast Cancer Res Treat 115, no. 1 (May 2009): 123-129. Full Text Link to Item
  - Carlson, RW, Allred, DC, Anderson, BO, Burstein, HJ, Carter, WB, Edge, SB, Erban, JK, Farrar, WB, Goldstein, LJ, Gradishar, WJ, Hayes, DF, Hudis, CA, Jahanzeb, M, Kiel, K, Ljung, B-M, Marcom, PK, Mayer, IA, McCormick, B, Nabell, LM, Pierce, LJ, Reed, EC, Smith, ML, Somlo, G, Theriault, RL, Topham, NS, Ward, JH, Winer, EP, Wolff, AC, and NCCN Breast Cancer Clinical Practice Guidelines Panel, . "Breast cancer. Clinical practice guidelines in oncology." J Natl Compr Canc Netw 7, no. 2 (February 2009): 122-192. (Review) Link to Item
  - Bild, AH, Parker, JS, Gustafson, AM, Acharya, CR, Hoadley, KA, Anders, C, Marcom, PK, Carey, LA, Potti, A, Nevins, JR, and Perou, CM. "An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer." Breast Cancer Res 11, no. 4 (2009): R55-. Full Text Link to Item
  - Buchanan, AH, Skinner, CS, Calingaert, B, Schildkraut, JM, King, RH, and Marcom, PK. "Cancer genetic counseling in rural north carolina oncology clinics: Program establishment and patient characteristics." Community Oncology 6, no. 2 (2009): 70-77.
  - Herold, CI, and Marcom, PK. "Primary systemic therapy in breast cancer: past lessons and new approaches." Cancer Invest 26, no. 10 (December 2008): 1052-1059. Full Text Link to Item
  - Anders, CK, Hsu, DS, Broadwater, G, Acharya, CR, Foekens, JA, Zhang, Y, Wang, Y, Marcom, PK, Marks, JR, Febbo, PG, Nevins, JR, Potti, A, and Blackwell, KL. "Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression." J Clin Oncol 26, no. 20 (July 10, 2008): 3324-3330. Full Text Link to Item
  - Liu, MC, Demetri, GD, Berry, DA, Norton, L, Broadwater, G, Robert, NJ, Duggan, D, Hayes, DF, Henderson, IC, Lyss, A, Hopkins, J, Kaufman, PA, Marcom, PK, Younger, J, Lin, N, Tkaczuk, K, Winer, EP, Hudis, CA, and Cancer and Leukemia Group B, . "Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel." Cancer Treat Rev 34, no. 3 (May 2008): 223-230. Full Text Link to Item
  - Olson, JA, and Marcom, PK. "Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer." Ann Surg 247, no. 5 (May 2008): 739-740. Full Text Link to Item
  - Acharya, CR, Hsu, DS, Anders, CK, Anguiano, A, Salter, KH, Walters, KS, Redman, RC, Tuchman, SA, Moylan, CA, Mukherjee, S, Barry, WT, Dressman, HK, Ginsburg, GS, Marcom, KP, Garman, KS, Lyman, GH, Nevins, JR, and Potti, A. "Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer." JAMA 299, no. 13 (April 2, 2008): 1574-1587. Full Text Link to Item
  - Salter, KH, Acharya, CR, Walters, KS, Redman, R, Anguiano, A, Garman, KS, Anders, CK, Mukherjee, S, Dressman, HK, Barry, WT, Marcom, KP, Olson, J, Nevins, JR, and Potti, A. "An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. (Published online)" PLoS One 3, no. 4 (April 2, 2008): e1908-. Full Text Open Access Copy Link to Item
  - Anders, C, Marcom, PK, Peterson, B, Gu, L, Unruhe, S, Welch, R, Lyons, P, Behera, M, Copland, S, Kimmick, G, Shaw, H, Snyder, S, Antenos, M, Woodruff, T, and Blackwell, K. "A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer." Cancer Invest 26, no. 3 (April 2008): 286-295. Full Text Link to Item
  - Seidman, AD, Berry, D, Cirrincione, C, Harris, L, Muss, H, Marcom, PK, Gipson, G, Burstein, H, Lake, D, Shapiro, CL, Ungaro, P, Norton, L, Winer, E, and Hudis, C. "Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840." J Clin Oncol 26, no. 10 (April 1, 2008): 1642-1649. Full Text Link to Item
  - Demark-Wahnefried, W, Case, LD, Blackwell, K, Marcom, PK, Kraus, W, Aziz, N, Snyder, DC, Giguere, JK, and Shaw, E. "Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy." Clin Breast Cancer 8, no. 1 (February 2008): 70-79. Full Text Link to Item
  - Anders, CK, Acharya, CR, Hsu, DS, Broadwater, G, Garman, K, Foekens, JA, Zhang, Y, Wang, Y, Marcom, K, Marks, JR, Mukherjee, S, Nevins, JR, Blackwell, KL, and Potti, A. "Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. (Published online)" PLoS One 3, no. 1 (January 2, 2008): e1373-. Full Text Open Access Copy Link to Item
  - Anders, C, Marcom, PK, Peterson, B, Gu, L, Unruhe, S, Welch, R, Lyons, P, Behera, M, Copland, S, Kimmick, G, Shaw, H, Snyder, S, Antenos, M, Woodruff, T, and Blackwell, K. "A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer (Cancer Investigation 26, 3, (286-295))." Cancer Investigation 26, no. 10 (2008): 1068--. Full Text
  - Polite, BN, Cirrincione, C, Fleming, GF, Berry, DA, Seidman, A, Muss, H, Norton, L, Shapiro, C, Bakri, K, Marcom, K, Lake, D, Schwartz, JH, Hudis, C, and Winer, EP. "Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840 - Cancer and leukemia group B." Journal of Clinical Oncology 26, no. 16 (2008): 2659-2665. Full Text
  - Morse, MA, Hobeika, A, Osada, T, Niedzwiecki, D, Marcom, PK, Blackwell, KL, Anders, C, Devi, GR, Lyerly, HK, and Clay, TM. "Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. (Published online)" J Transl Med 5 (September 6, 2007): 42-. Full Text Link to Item
  - Burstein, HJ, Keshaviah, A, Baron, AD, Hart, RD, Lambert-Falls, R, Marcom, PK, Gelman, R, and Winer, EP. "Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study." Cancer 110, no. 5 (September 1, 2007): 965-972. Full Text Link to Item
  - Lehman, CD, Isaacs, C, Schnall, MD, Pisano, ED, Ascher, SM, Weatherall, PT, Bluemke, DA, Bowen, DJ, Marcom, PK, Armstrong, DK, Domchek, SM, Tomlinson, G, Skates, SJ, and Gatsonis, C. "Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study." Radiology 244, no. 2 (August 2007): 381-388. Full Text Link to Item
  - Marcom, PK, Isaacs, C, Harris, L, Wong, ZW, Kommarreddy, A, Novielli, N, Mann, G, Tao, Y, and Ellis, MJ. "The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers." Breast Cancer Res Treat 102, no. 1 (March 2007): 43-49. Full Text Link to Item
  - Bean, GR, Ibarra Drendall, C, Goldenberg, VK, Baker, JC, Troch, MM, Paisie, C, Wilke, LG, Yee, L, Marcom, PK, Kimler, BF, Fabian, CJ, Zalles, CM, Broadwater, G, Scott, V, and Seewaldt, VL. "Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 16, no. 1 (January 2007): 50-56. Full Text
  - Marcom, PK. "Genetic Nurse Counsellors Can Be An Acceptable and Cost-effective Alternative to Clinical Geneticists for Breast Cancer Risk Genetic Counselling. Evidence From Two Parallel Randomised Controlled Equivalence Trials." Breast Diseases 18, no. 2 (2007): 212--. Full Text
  - Daly, MB, Axilbund, JE, Bryant, E, Buys, S, Eng, C, Friedman, S, Esserman, LJ, Farrell, CD, Ford, JM, Garber, JE, Jeter, JM, Kohlmann, W, Lynch, PM, Marcom, PK, Nabell, LM, Offit, K, Osarogiagbon, RU, Pasche, B, Reiser, G, Sutphen, R, Weitzel, JN, and National Comprehensive Cancer Network, . "Genetic/familial high-risk assessment: breast and ovarian." J Natl Compr Canc Netw 4, no. 2 (February 2006): 156-176. Link to Item
  - Dressman, HK, Hans, C, Bild, A, Olson, JA, Rosen, E, Marcom, PK, Liotcheva, VB, Jones, EL, Vujaskovic, Z, Marks, J, Dewhirst, MW, West, M, Nevins, JR, and Blackwell, K. "Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy." Clin Cancer Res 12, no. 3 Pt 1 (February 1, 2006): 819-826. Full Text Link to Item
  - Daly, MB, Axilbund, JE, Bryant, E, Buys, S, Eng, C, Friedman, S, Esserman, LJ, Farrell, CD, Ford, JM, Garber, JE, Jeter, JM, Kohlmann, W, Lynch, PM, Marcom, PK, Nabell, LM, Offit, K, Osarogiagbon, RU, Pasche, B, Reiser, G, Sutphen, R, and Weitzel, JN. "Genetic/familial high-risk assessment: Breast and ovarian. Clinical Practice Guidelines in Oncology™." JNCCN Journal of the National Comprehensive Cancer Network 4, no. 2 (2006): 156-176.
  - Burris, HA, Hurwitz, HI, Dees, EC, Dowlati, A, Blackwell, KL, O'Neil, B, Marcom, PK, Ellis, MJ, Overmoyer, B, Jones, SF, Harris, JL, Smith, DA, Koch, KM, Stead, A, Mangum, S, and Spector, NL. "Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas." J Clin Oncol 23, no. 23 (August 10, 2005): 5305-5313. Full Text Link to Item
  - Spector, NL, Xia, W, Burris, H, Hurwitz, H, Dees, EC, Dowlati, A, O'Neil, B, Overmoyer, B, Marcom, PK, Blackwell, KL, Smith, DA, Koch, KM, Stead, A, Mangum, S, Ellis, MJ, Liu, L, Man, AK, Bremer, TM, Harris, J, and Bacus, S. "Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies." J Clin Oncol 23, no. 11 (April 10, 2005): 2502-2512. Full Text Link to Item
  - Bean, GR, Scott, V, Yee, L, Ratliff-Daniel, B, Troch, MM, Seo, P, Bowie, ML, Marcom, PK, Slade, J, Kimler, BF, Fabian, CJ, Zalles, CM, Broadwater, G, Baker, JC, Wilke, LG, and Seewaldt, VL. "Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 14, no. 4 (April 2005): 790-798. Full Text
  - Miller, KD, Chap, LI, Holmes, FA, Cobleigh, MA, Marcom, PK, Fehrenbacher, L, Dickler, M, Overmoyer, BA, Reimann, JD, Sing, AP, Langmuir, V, and Rugo, HS. "Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer." J Clin Oncol 23, no. 4 (February 1, 2005): 792-799. Full Text Link to Item
  - Jones, EL, Prosnitz, LR, Dewhirst, MW, Marcom, PK, Hardenbergh, PH, Marks, LB, Brizel, DM, and Vujaskovic, Z. "Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer." Clin Cancer Res 10, no. 13 (July 1, 2004): 4287-4293. Full Text Link to Item
  - Gradishar, WJ, Meza, LA, Amin, B, Samid, D, Hill, T, Chen, Y-M, Lower, EE, and Marcom, PK. "Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study." J Clin Oncol 22, no. 12 (June 15, 2004): 2321-2327. Full Text Link to Item
  - Gradishar, WJ, Meza, LA, Amin, B, Samid, D, Hill, T, Chen, Y-M, Lower, EE, Marcom, PK, and Iqbal, S. "Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study." Women's Oncology Review 4, no. 4 (2004): 283-285. Full Text
  - Jones, EL, Prosnitz, LR, Dewhirst, MW, Marcom, PK, Hardenbergh, PH, Marks, LB, Brizel, DM, Vujaskovic, Z, and Buchholz, TA. "Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer." Women's Oncology Review 4, no. 3 (2004): 221-222. Full Text
  - Burstein, HJ, Harris, LN, Marcom, PK, Lambert-Falls, R, Havlin, K, Overmoyer, B, Friedlander, RJ, Gargiulo, J, Strenger, R, Vogel, CL, Ryan, PD, Ellis, MJ, Nunes, RA, Bunnell, CA, Campos, SM, Hallor, M, Gelman, R, and Winer, EP. "Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm." J Clin Oncol 21, no. 15 (August 1, 2003): 2889-2895. Full Text Link to Item
  - Partridge, AH, Burstein, HJ, Gelman, RS, Marcom, PK, and Winer, EP. "Do patients participating in clinical trials want to know study results?." J Natl Cancer Inst 95, no. 6 (March 19, 2003): 491-492. (Letter) Link to Item
  - Dietze, EC, Caldwell, LE, Marcom, K, Collins, SJ, Yee, L, Swisshelm, K, Hobbs, KB, Bean, GR, and Seewaldt, VL. "Retinoids and retinoic acid receptors regulate growth arrest and apoptosis in human mammary epithelial cells and modulate expression of CBP/p300." Microsc Res Tech 59, no. 1 (October 1, 2002): 23-40. Full Text Link to Item
  - Skinner, CS, Schildkraut, JM, Berry, D, Calingaert, B, Marcom, PK, Sugarman, J, Winer, EP, Iglehart, JD, Futreal, PA, and Rimer, BK. "Pre-counseling education materials for BRCA testing: does tailoring make a difference?." Genet Test 6, no. 2 (2002): 93-105. Full Text Link to Item
  - Demark-Wahnefried, W, Peterson, BL, Winer, EP, Marks, L, Aziz, N, Marcom, PK, Blackwell, K, and Rimer, BK. "Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy." J Clin Oncol 19, no. 9 (May 1, 2001): 2381-2389. Full Text Link to Item
  - Miron, A, Schildkraut, JM, Rimer, BK, Winer, EP, Sugg Skinner, C, Futreal, PA, Culler, D, Calingaert, B, Clark, S, Kelly Marcom, P, and Iglehart, JD. "Testing for hereditary breast and ovarian cancer in the southeastern United States." Ann Surg 231, no. 5 (May 2000): 624-634. Link to Item
  - Burstein, HJ, Ramirez, MJ, Petros, WP, Clarke, KD, Warmuth, MA, Marcom, PK, Matulonis, UA, Parker, LM, Harris, LN, and Winer, EP. "Phase I study of Doxil and vinorelbine in metastatic breast cancer." Ann Oncol 10, no. 9 (September 1999): 1113-1116. Link to Item
  - Ortel, TL, Charles, LA, Keller, FG, Marcom, PK, Oldham, HN, Kane, WH, and Macik, BG. "Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis." Am J Hematol 45, no. 2 (February 1994): 128-135. (Review) Link to Item
  - Kirkland, KB, Marcom, PK, Sexton, DJ, Dumler, JS, and Walker, DH. "Rocky Mountain spotted fever complicated by gangrene: report of six cases and review." Clin Infect Dis 16, no. 5 (May 1993): 629-634. (Review) Link to Item
  - Noebels, JL, Marcom, PK, and Jalilian-Tehrani, MH. "Sodium channel density in hypomyelinated brain increased by myelin basic protein gene deletion." Nature 352, no. 6334 (August 1, 1991): 431-434. Full Text Link to Item
- Other Articles
  - Aziz, H, Marcom, PK, and Hwang, ES. "Implications of HER2-targeted therapy on extent of surgery for early-stage breast cancer." Annals of surgical oncology 22, no. 5 (May 2015): 1404-1405. Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Grants

Selected Publications

Conference Papers

Journal Articles

Other Articles